The market opened in the green on April 17, 2020. The previous trading session witnessed the Sensex going up by 222.80 points to end at 30,602.61 and the Nifty was up 67.50 points to close at 8,992.80.

Sudarshan Chemical Industries Limited has informed the bourses that it has received necessary permissions to restart production at its manufacturing facility located at Mahad (Maharashtra).

RBI Governor also said that the IIP data released earlier witnessed that 4.5 per cent growth has not captured the impact caused by COVID-19 so, we should not be misled by the data.

L&T is one of the largest engineering, technology, construction and financial services conglomerate. It classifies its order book in four major categories such as significant, large, major and mega.

On Thursday, India’s largest IT firm, Tata Consultancy Services reported its fourth quarter result of FY20. Its consolidated revenue for the quarter was at Rs 39,946 crore which largely flat compared to Rs 39,854 crore in the previous quarter of the same fiscal year

The market opened in the green on April 17, 2020, overall volumes in futures & options currently stand at 4,10 crore contracts with a turnover of Rs. 19,55,639.67 crore.

The market opened in the green on April 17, 2020, overall volumes in futures & options currently stand at 4,10 crore contracts with a turnover of Rs. 19,55,639.67 crore.

The company has taken this step as the demand for hand sanitisers reaches a new peak amidst the recent spread of COVID-19 global pandemic. The company could be beneficial as there is a huge gap in the demand & supply of hand sanitisers in the market.

Nifty has continued its sequence of higher highs and higher lows. On the upside, sustaining above 9,132 level could open up for further upside, towards the levels of 9,390. Stocks in news: Sudarshan Chemical, Graphite India, M&M, JK Lakshmi Cement, Grindwell Norton.

The markets showed some signs of strength in the previous session as the speed and urgency shown by multiple pharmaceuticals companies to find a resolution to COVID-19 is a good sign. Further, the optimism has been flamed after a report stated that Gilead’s drug is one of the most-watched therapies being studied for the treatment of COVID-19 patients.